Methylation and expression of miRNAs in precancerous lesions and cervical cancer with HPV16 infection

Oncology Reports
Hilda Jiménez-WencesGloria Fernández-Tilapa

Abstract

Abnormal expression and promoter methylation of microRNAs (miRNAs) are common events during cervical carcinogenesis. Worldwide, infection by types 18 and 16 of human papillomaviruses (HPVs) is considered the major risk factor for cervical cancer development. It has been reported that expression of the miRNAs can be deregulated by specific HPV genotypes. In this study we analyzed the promoter methylation of 22 miRNAs and the expression of three miRNAs in 10 non-squamous intraepithelial lesions (Non-SIL) without HPV16 infection, and 7 Non-SIL, 16 low-grade SIL (LSIL) and 16 cervical cancer samples, all with HPV16 infection. The methylation status was determined using Human Cancer miRNA EpiTect Methyl II Signature PCR Array® and the expression of miR-124, miR-218 and miR-193b was determined by qRT-PCR using individual TaqMan assays. Comparisons of groups defined were performed using the Fisher exact test for categorical variables and Mann-Whitney test for continuous variables. A p-value of <0.05 was considered statistically significant. The methylation levels of miR-124-2, miR-218-1, miR-218-2 and miR-34b/c promoters were significantly higher in cervical cancer than in LSIL samples. The methylation levels of miR-193b promoter were...Continue Reading

References

Apr 23, 2002·JAMA : the Journal of the American Medical Association·Diane SolomonUNKNOWN Bethesda 2001 Workshop
Jun 5, 2002·Nature Reviews. Cancer·Harald zur Hausen
Dec 20, 2005·The Journal of Pathology·Peter J F SnijdersChris J L M Meijer
Feb 20, 2007·Cancer Research·Amaia LujambioManel Esteller
Jan 18, 2008·Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology·Tiffany G HarrisHoward D Strickler
Jun 13, 2008·Nature Protocols·Thomas D Schmittgen, Kenneth J Livak
Aug 23, 2008·Cell Cycle·Dmitri LodyginHeiko Hermeking
Sep 5, 2008·Proceedings of the National Academy of Sciences of the United States of America·Amaia LujambioManel Esteller
Nov 22, 2008·Cancer Detection and Prevention·Berenice Illades-AguiarMarco-Antonio Leyva-Vázquez
Jan 15, 2010·International Journal of Cancer. Journal International Du Cancer·Hanna E RauhalaTapio Visakorpi
Jun 29, 2010·Molecular Cancer·Saskia M WiltingRenske D M Steenbergen
Feb 11, 2012·International Journal of Cancer. Journal International Du Cancer·Peng GuanGary M Clifford
Apr 12, 2012·Acta Biochimica Et Biophysica Sinica·Huajun HuBin Ni
Jul 18, 2012·Cell Cycle·Tak-hong CheungYick-fu Wong
Jan 18, 2013·Epigenetics : Official Journal of the DNA Methylation Society·Saskia M WiltingRenske D M Steenbergen
Jan 22, 2013·PloS One·Michelle LenarduzziFei-Fei Liu
May 31, 2013·The Journal of Clinical Endocrinology and Metabolism·Hongyu GuanYanbing Li
Dec 19, 2013·Frontiers in Genetics·Hiromu SuzukiMasahiro Kai
Feb 6, 2014·Journal of Neuroscience Research·Qisheng ZhongShaoji Yuan
Mar 5, 2014·Proceedings of the National Academy of Sciences of the United States of America·Xiaohong WangZhi-Ming Zheng
Oct 9, 2014·BioMed Research International·Yasuto KinoseTadashi Kimura

❮ Previous
Next ❯

Citations

May 21, 2016·Journal of Translational Medicine·Lyudmila F Gulyaeva, Nicolay E Kushlinskiy
Feb 20, 2019·Journal of Cellular Physiology·Monireh KhordadmehrBehzad Baradaran
Mar 7, 2019·American Journal of Physiology. Cell Physiology·Qingyi MaWilliam J Pearce
Feb 27, 2020·Journal of Clinical Laboratory Analysis·Haizhen HeLiqin Cao
Feb 7, 2017·Expert Reviews in Molecular Medicine·D TsakogiannisP Markoulatos
Aug 21, 2019·Cancer Cell International·Sacnite Del Mar Díaz-GonzálezOscar Peralta-Zaragoza
Jun 28, 2018·BMC Cancer·Barbara PardiniAlessio Naccarati
Nov 21, 2019·Molecular Medicine Reports·Zhen LiuXiaoxia Hu
Aug 14, 2020·International Journal of Molecular Sciences·Iwona Rzeszutek, Aditi Singh
Oct 29, 2020·APMIS : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica·Rodolfo Ocadiz-DelgadoPatricio Gariglio
Nov 19, 2020·Journal of Clinical Medicine·Justyna Pisarska, Katarzyna Baldy-Chudzik
Feb 18, 2021·Biomedical Engineering Online·Leonardo J Galvão-LimaElio J S S Barreto
Mar 17, 2020·Gene·Vida EbrahimiVahideh Tarhriz
Aug 14, 2021·Obstetrics & Gynecology Science·Kavitha NagandlaMohamed Faiz Bin Mohamed Jamli
May 2, 2018·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Xin Liu

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.

Cancer Epigenetics & Methyl-CpG (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. Here is the latest research on cancer epigenetics and methyl-CpG binding proteins including ZBTB38.

Cancer Epigenetics and Senescence (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may be involved in regulating senescence in cancer cells. This feed captures the latest research on cancer epigenetics and senescence.

Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cell Signaling & Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. This feed covers the latest research on signaling and epigenetics in cell growth and cancer.

Related Papers

Infectious Agents and Cancer
Gabriela Elizabeth Campos-ViguriGloria Fernández-Tilapa
International Journal of Clinical and Experimental Medicine
Diana K Jiménez TagleLuz Del Carmen Alarcón Romero
International Journal of Gynaecology and Obstetrics : the Official Organ of the International Federation of Gynaecology and Obstetrics
M TemmermanW Quint
Cellular Oncology : the Official Journal of the International Society for Cellular Oncology
Nan YangAte G J van der Zee
© 2022 Meta ULC. All rights reserved